First Drug, Nucala (Mepolizumab), Approved for Rare Eosinophilic Granulomatosis With Polyangiitis

TUESDAY, Dec. 12, 2017 — Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration as the first remedy to treat adults with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease that leads to inflammation of…
Source: Topamax